Literature DB >> 10804144

Structural studies of recombinant Norwalk capsids.

B V Venkataram Prasad1, M E Hardy, M K Estes.   

Abstract

Norwalk virus is the major cause of epidemic viral gastroenteritis in humans. Attempts to grow this human virus in laboratory cell lines have been unsuccessful; however, the Norwalk virus capsid protein, when expressed in insect cells infected with a recombinant baculovirus, spontaneously assembles into virus-like particles. The x-ray crystallographic structure of these recombinant Norwalk particles has been determined to 3.4 A, using a 22-A electron cryomicroscopy structure as a phasing model. The recombinant capsids, 380 A in diameter, exhibit a T=3 icosahedral symmetry. The capsid is formed by 90 dimers of the capsid protein, each of which forms an arch-like capsomere. The capsid protein has two distinct domains-a shell (S) and a protruding (P) domain-that are connected by a flexible hinge. Although the S domain has a classical beta-sandwich fold, the structure of the P domain is unlike any other viral protein. One of the subdomains in the P domain formed by the most variable part of the sequence is located at the exterior of the capsid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804144     DOI: 10.1086/315576

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Diffusion of macromolecules and virus-like particles in human cervical mucus.

Authors:  S S Olmsted; J L Padgett; A I Yudin; K J Whaley; T R Moench; R A Cone
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

2.  Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype.

Authors:  Mikael Nilsson; Kjell-Olof Hedlund; Margareta Thorhagen; Göran Larson; Kari Johansen; Anders Ekspong; Lennart Svensson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Genetic variability in the sapovirus capsid protein.

Authors:  Mineyuki Okada; Yasutaka Yamashita; Mitsuaki Oseto; Tomoko Ogawa; Ikuo Kaiho; Kuniko Shinozaki
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

4.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

5.  Structural requirements for the assembly of Norwalk virus-like particles.

Authors:  Andrea Bertolotti-Ciarlet; Laura J White; Rong Chen; B V Venkataram Prasad; Mary K Estes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 6.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

7.  Cryo-electron microscopy reconstructions of two types of wild rabbit hemorrhagic disease viruses characterized the structural features of Lagovirus.

Authors:  Zhongjun Hu; Xiaojuan Tian; Yujia Zhai; Wei Xu; Dong Zheng; Fei Sun
Journal:  Protein Cell       Date:  2010-02-07       Impact factor: 14.870

Review 8.  Norwalk virus-like particles as vaccines.

Authors:  Melissa Herbst-Kralovetz; Hugh S Mason; Qiang Chen
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

9.  Chlorine inactivation of adenovirus type 40 and feline calicivirus.

Authors:  Jeanette A Thurston-Enriquez; Charles N Haas; Joseph Jacangelo; Charles P Gerba
Journal:  Appl Environ Microbiol       Date:  2003-07       Impact factor: 4.792

10.  Structure of antibody-neutralized murine norovirus and unexpected differences from viruslike particles.

Authors:  Umesh Katpally; Christiane E Wobus; Kelly Dryden; Herbert W Virgin; Thomas J Smith
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.